Novo Nordisk's US stock rose more than 8% before the market opened. Clinical trials showed that its weight loss drug Amycretin reduced body weight by 22%.

2025-01-24 10:38:33

Novo Nordisk's US stock rose more than 8% in pre-market trading. The company announced the results of a Phase 1b/2a clinical trial for Amycretin. Patients treated with Amycretin lost 9.7% of their body weight after 20 weeks, 16.2% after 28 weeks, and 22.0% after 36 weeks. Based on this result, Novo Nordisk is planning to further develop Amycretin for overweight or obese adults.

weight loss drug Novo Nordisk

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Intel's US stock rose more than 10% in the night trading
                            2025-03-12

                                    360 launches DS large model security solution to protect the development of DeepSeek
                            2025-03-12

                                    JD.com's revenue in Q4 2024 is expected to be 347 billion yuan
                            2025-03-06

                                    Daiwa Securities raised Alibaba Group's target price from HK$165 to HK$175
                            2025-03-07

                                    Ouye Semiconductor completed B2 round of financing of hundreds of millions of yuan to promote large-scale application of products
                            2025-03-13